|
EP2352763B2
(en)
*
|
2008-10-01 |
2022-09-21 |
Amgen Research (Munich) GmbH |
Bispecific single chain antibodies with specificity for high molecular weight target antigens
|
|
EP3275461A1
(en)
*
|
2011-09-19 |
2018-01-31 |
Axon Neuroscience SE |
Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
EP4624490A3
(en)
|
2012-02-09 |
2025-11-05 |
Chugai Seiyaku Kabushiki Kaisha |
Modified fc region of antibody
|
|
EP2906596B1
(en)
*
|
2012-10-12 |
2023-12-27 |
Arizona Board of Regents on behalf of Arizona State University |
Antibody based reagents that specifically recognize toxic oligomeric forms of tau
|
|
WO2014165271A2
(en)
|
2013-03-13 |
2014-10-09 |
Neotope Biosciences Limited |
Tau immunotherapy
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
CR20160270A
(es)
*
|
2013-12-20 |
2016-09-05 |
Hoffmann La Roche |
ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
|
|
JP6510532B2
(ja)
*
|
2013-12-20 |
2019-05-08 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性ｈｅｒ２抗体及び使用方法
|
|
CA2938066C
(en)
*
|
2014-02-02 |
2025-05-06 |
Medimmune Limited |
CHIMERIC PROTEIN COMPOSED OF NERVE GROWTH FACTOR ANTAGONIST DOMAIN AND TUMOR NECROSIS FACTOR-ANTAGONIST DOMAIN-A
|
|
US9856324B2
(en)
*
|
2014-06-04 |
2018-01-02 |
MabVax Therapeutics, Inc. |
Human monoclonal antibodies to ganglioside GD2
|
|
CA2960925A1
(en)
*
|
2014-09-30 |
2016-04-07 |
Neurimmune Holding Ag |
Human-derived anti-dipeptide repeats (dprs) antibody
|
|
JP6696982B2
(ja)
|
2014-11-26 |
2020-05-20 |
ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． |
Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体
|
|
NZ775762A
(en)
|
2015-06-05 |
2025-02-28 |
Genentech Inc |
Anti-tau antibodies and methods of use
|
|
ES2809728T3
(es)
|
2015-06-24 |
2021-03-05 |
Hoffmann La Roche |
Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
|
|
CA2990785C
(en)
*
|
2015-06-24 |
2024-11-12 |
Jcr Pharmaceuticals Co., Ltd. |
ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
|
|
HK1247933A1
(en)
|
2015-06-24 |
2018-10-05 |
Jcr Pharmaceuticals Co., Ltd. |
Fusion protein containing bdnf
|
|
CA2991264C
(en)
|
2015-07-06 |
2023-10-10 |
Ucb Biopharma Sprl |
Tau-binding antibodies
|
|
SG10202010735PA
(en)
|
2015-07-06 |
2020-11-27 |
UCB Biopharma SRL |
Tau-binding antibodies
|
|
PT3334761T
(pt)
*
|
2015-08-13 |
2023-08-17 |
Univ New York |
Moléculas baseadas em anticorpo seletivo para o epítopo {p}ser404 da tau e os seus usos no diagnóstico e tratamento de tauopatias
|
|
WO2017176835A2
(en)
*
|
2016-04-06 |
2017-10-12 |
Imago Pharmaceuticals, Inc. |
Therapeutic antibodies for treatment of neurodegeneration
|
|
EP3452507B1
(en)
|
2016-05-02 |
2022-10-19 |
Prothena Biosciences Limited |
Tau immunotherapy
|
|
US10906964B2
(en)
|
2016-05-02 |
2021-02-02 |
Prothena Biosciences Limited |
Antibodies recognizing tau
|
|
MX2018013384A
(es)
|
2016-05-02 |
2019-02-28 |
Prothena Biosciences Ltd |
Anticuerpos que reconocen tau.
|
|
SG11201811184UA
(en)
|
2016-06-20 |
2019-01-30 |
F Star Beta Ltd |
Lag -3 binding members
|
|
US10570196B2
(en)
*
|
2016-07-20 |
2020-02-25 |
Anahit Ghochikyan |
Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
|
|
WO2018018031A1
(en)
*
|
2016-07-22 |
2018-01-25 |
New York University |
Specific murine and humanized monoclonal antibodies detecting pathology associated secondary structure changes in proteins and peptides
|
|
EP3551220B1
(en)
|
2016-12-07 |
2025-01-29 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
|
EP3551655A2
(en)
*
|
2016-12-07 |
2019-10-16 |
Genentech, Inc. |
Anti-tau antibodies and methods of their use
|
|
CN110366564B
(zh)
*
|
2016-12-23 |
2023-07-07 |
瑞美德生物医药科技有限公司 |
使用与程序性死亡1(pd-1)结合的抗体的免疫疗法
|
|
TWI791006B
(zh)
|
2016-12-26 |
2023-02-01 |
日商Ｊｃｒ製藥股份有限公司 |
包含bdnf之融合蛋白質
|
|
TWI833178B
(zh)
*
|
2016-12-26 |
2024-02-21 |
日商Ｊｃｒ製藥股份有限公司 |
通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
|
|
US12049493B2
(en)
*
|
2017-01-06 |
2024-07-30 |
Abl Bio Inc. |
Anti-alpha-synuclein antibodies and uses thereof
|
|
KR20260069620A
(ko)
*
|
2017-01-30 |
2026-05-15 |
알렉시온 파마슈티칼스, 인코포레이티드 |
1가 항-프로페르딘 항체 및 항체 단편
|
|
KR20190129859A
(ko)
*
|
2017-02-10 |
2019-11-20 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
항-d 인자 항체 및 그의 용도
|
|
EP3592386A4
(en)
*
|
2017-03-06 |
2021-01-13 |
The Trustees Of The University Of Pennsylvania |
ANTI-C5 ANTIBODIES AND USES THEREOF
|
|
MX2019011252A
(es)
*
|
2017-03-23 |
2020-01-23 |
Univ Pennsylvania |
Anticuerpos anti-c5a y usos de los mismos.
|
|
WO2018178076A1
(en)
*
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
|
CN110691793A
(zh)
*
|
2017-04-26 |
2020-01-14 |
田边三菱制药株式会社 |
黏结蛋白聚糖-1（cd138）结合剂及其用
|
|
SG11201910066QA
(en)
|
2017-05-02 |
2019-11-28 |
Prothena Biosciences Ltd |
Antibodies recognizing tau
|
|
JP7761373B2
(ja)
*
|
2017-05-30 |
2025-10-28 |
ザ ユニヴァーシティ オブ ブリティッシュ コロンビア |
Ｔｄｐ－４３のｒｎａ認識モチーフ１（ｒｒｍ１）中のエピトープ、およびそれらに対するミスフォールディング選択的抗体
|
|
EP3431496A1
(en)
*
|
2017-07-19 |
2019-01-23 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti- isoasp7 amyloid beta antibodies and uses thereof
|
|
CN111201030B
(zh)
|
2017-07-25 |
2024-11-01 |
真和制药有限公司 |
通过阻断tim-3和其配体的相互作用治疗癌症
|
|
EP3661961A4
(en)
*
|
2017-08-02 |
2021-04-14 |
Stressmarq Biosciences Inc. |
ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN
|
|
EP3694883A1
(en)
*
|
2017-10-12 |
2020-08-19 |
Keio University |
Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
|
|
WO2019108806A1
(en)
*
|
2017-11-29 |
2019-06-06 |
Board Of Regents Of The University Of Texas System |
Compositions and methods for cancer therapy
|
|
AU2018379306A1
(en)
*
|
2017-12-05 |
2020-06-25 |
Mabion Sa |
Combination therapy of multiple sclerosis comprising a CD20 ligand
|
|
WO2019113711A1
(en)
|
2017-12-14 |
2019-06-20 |
University Of Ottawa |
Exosome packaging and targeted autophagy
|
|
WO2019118906A2
(en)
*
|
2017-12-14 |
2019-06-20 |
University Of Florida Research Foundation |
Monoclonal antibodies targeting phf1 and at8 epitopes of human tau protein
|
|
BR112020011875A2
(pt)
|
2017-12-14 |
2020-11-24 |
Abl Bio Inc. |
anticorpo biespecífico ao a-syn/igf1r e uso do mesmo
|
|
CN118271444A
(zh)
|
2017-12-19 |
2024-07-02 |
瑟罗泽恩奥普瑞汀公司 |
Wnt替代分子和其用途
|
|
CN111699003B
(zh)
*
|
2017-12-19 |
2024-05-03 |
瑟罗泽恩奥普瑞汀公司 |
抗lrp5/6抗体和使用方法
|
|
CN111886246B
(zh)
|
2017-12-29 |
2024-12-17 |
艾莱克特有限责任公司 |
抗tmem106b抗体及其使用方法
|
|
US11466077B2
(en)
*
|
2018-01-05 |
2022-10-11 |
Ac Immune Sa |
Misfolded TDP-43 binding molecules
|
|
WO2019148204A1
(en)
*
|
2018-01-29 |
2019-08-01 |
The Regents Of The University Of California |
Therapies and methods to treat tlr2-mediated diseases and disorders
|
|
EP3746476A1
(en)
|
2018-01-31 |
2020-12-09 |
Alector LLC |
Anti-ms4a4a antibodies and methods of use thereof
|
|
EP3746484A4
(en)
|
2018-01-31 |
2021-11-17 |
Alector LLC |
ANTI-MS4A6A ANTIBODY AND METHOD OF USING THEREOF
|
|
JP7539834B2
(ja)
*
|
2018-02-01 |
2024-08-26 |
メモリアル スローン ケタリング キャンサー センター |
ガレクチン－３に対する抗体及びその使用方法
|
|
US12398201B2
(en)
*
|
2018-02-19 |
2025-08-26 |
New York University |
Tau single domain antibodies
|
|
US12492254B2
(en)
|
2018-02-23 |
2025-12-09 |
H. Lee Moffitt Cancer Center and Research Intitute. Inc. |
CD83-binding chimeric antigen receptors
|
|
AU2019236105B2
(en)
|
2018-03-14 |
2025-07-31 |
Boehringer Ingelheim International Gmbh |
Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
|
|
WO2019180576A1
(en)
*
|
2018-03-20 |
2019-09-26 |
Novartis Ag |
Pharmaceutical combinations
|
|
CA3095498A1
(en)
*
|
2018-04-09 |
2019-10-17 |
Origincell Therapeutics Co., Ltd. |
Anti-pd-l1 antibody and use thereof
|
|
EP3773707A1
(en)
*
|
2018-04-11 |
2021-02-17 |
Tychan Pte. Ltd. |
Methods and compositions for treating yellow fever
|
|
JP2021521273A
(ja)
*
|
2018-04-12 |
2021-08-26 |
メディアファーマ エス．アール．エル． |
Ｌｇａｌｓ３ｂｐ抗体−薬剤結合体及びがん治療のためのその使用
|
|
KR102866162B1
(ko)
*
|
2018-04-24 |
2025-10-01 |
주식회사 뉴라클사이언스 |
신경병성 통증의 치료를 위한 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리의 용도
|
|
US20210054079A1
(en)
*
|
2018-04-25 |
2021-02-25 |
Medimmune Limited |
Formulations of human anti-pd-li antibodies
|
|
BR112020021855A2
(pt)
|
2018-04-27 |
2021-02-23 |
Biogen Ma Inc. |
anticorpo antirrepetição de dipeptídeo (dpr) (poli-ga) derivado de humanos
|
|
GB201806918D0
(en)
*
|
2018-04-27 |
2018-06-13 |
Enleofen Bio Pte Ltd |
Combination treatment for eye fibrosis
|
|
WO2019224724A1
(en)
*
|
2018-05-23 |
2019-11-28 |
Glaxosmithkline Intellectual Property Development Limited |
Biopharmaceutical compositions comprising antibody variants
|
|
WO2019225787A1
(ko)
*
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
|
US11578125B2
(en)
*
|
2018-05-29 |
2023-02-14 |
Teknologian Tutkimuskeskus Vtt Oy |
Anti-thyroid hormone (T4) recombinant antibody or antigen binding fragment
|
|
WO2019229155A1
(en)
*
|
2018-05-31 |
2019-12-05 |
Glenmark Pharmceuticals S.A. |
Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders
|
|
CN110577597B
(zh)
*
|
2018-06-11 |
2021-10-22 |
康诺亚生物医药科技（成都）有限公司 |
一种阻断CD47和SIRPα相互作用的抗体
|
|
EP3806902A4
(en)
*
|
2018-06-14 |
2022-05-04 |
Beth Israel Deaconess Medical Center, Inc. |
COMPOSITIONS AND METHODS TO PREVENT OR REVERSE T-CELL DEPLETION BY ECTONUCLEOTIDASE INHIBITION AND ANTIBODY-MEDIATED TARGET CYTOSIS
|
|
JP7513533B2
(ja)
*
|
2018-07-02 |
2024-07-09 |
アブセントラ，エルエルシー |
リポタンパク質ａの形成を減少させるための組成物及び方法、ならびに大動脈弁硬化症及び大動脈弁狭窄症の治療
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
BR112021000394A2
(pt)
|
2018-07-12 |
2021-04-06 |
F-Star Beta Limited |
Moléculas de anticorpo que se ligam a pd-l1 e cd137
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
GB201811404D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
AU2019301206B2
(en)
*
|
2018-07-12 |
2025-10-30 |
Invox Pharma Limited |
Antibody molecules that bind CD137 and OX40
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
CN110713537B
(zh)
*
|
2018-07-13 |
2023-04-21 |
江苏怀瑜药业有限公司 |
一种sema4d抗体及其制备方法和应用
|
|
CN112513078B
(zh)
*
|
2018-07-31 |
2022-11-18 |
沈为群 |
抗il-17a抗体及其用途
|
|
EP3833391A4
(en)
*
|
2018-08-08 |
2022-08-10 |
Orionis Biosciences, Inc. |
ANTI-SIRP1ALPHA CHIMERIC PROTEINS AND USES THEREOF
|
|
US12173070B2
(en)
*
|
2018-08-21 |
2024-12-24 |
Abl Bio Inc. |
Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof
|
|
CN113038967B
(zh)
|
2018-09-06 |
2026-07-14 |
宾夕法尼亚大学理事会 |
人源化抗c5抗体及其用途
|
|
CN111253485A
(zh)
*
|
2018-11-30 |
2020-06-09 |
上海开拓者生物医药有限公司 |
抗人tim-3单克隆抗体及其应用
|
|
SG11202105152YA
(en)
*
|
2018-11-30 |
2021-06-29 |
Abl Bio Inc |
Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
|
|
US12269874B2
(en)
*
|
2018-12-03 |
2025-04-08 |
mAbProtein Co., Ltd. |
Antibody that recognizes neoepitope of activated interleukin-18 proteins and application thereof
|
|
WO2020123447A1
(en)
*
|
2018-12-11 |
2020-06-18 |
The Regents Of The University Of California |
Compositions and methods for immunotherapies
|
|
TWI734279B
(zh)
*
|
2018-12-14 |
2021-07-21 |
美商美國禮來大藥廠 |
抗α-突觸核蛋白抗體及其用途
|
|
KR20210124308A
(ko)
|
2019-01-30 |
2021-10-14 |
트루바인딩 아이엔씨. |
항-gal3 항체 및 이의 용도
|
|
US11254736B2
(en)
*
|
2019-02-15 |
2022-02-22 |
Integral Molecular, Inc. |
Antibodies comprising a common light chain and uses thereof
|
|
CN119708241A
(zh)
*
|
2019-02-15 |
2025-03-28 |
因特格尔莫来库乐有限公司 |
密封蛋白6抗体及其用途
|
|
SG11202108655TA
(en)
*
|
2019-02-15 |
2021-09-29 |
Univ Southern California |
Lym-1 and lym-2 antibody compositions and improved car constructs
|
|
TWI859197B
(zh)
|
2019-03-03 |
2024-10-21 |
愛爾蘭商普羅帝納生物科學公司 |
識別ｔａｕ之抗體
|
|
EP3947445A1
(en)
*
|
2019-04-04 |
2022-02-09 |
Vanderbilt University |
Hiv/hcv cross-reactive antibodies and uses thereof
|
|
US20220220196A1
(en)
*
|
2019-04-24 |
2022-07-14 |
Janssen Biotech, Inc. |
Antibody formulation
|
|
AU2020267953A1
(en)
*
|
2019-05-08 |
2021-11-18 |
Novartis Ag |
Anti-CD40 antibodies for use in treatment of T1DM and insulitis
|
|
WO2020230106A1
(en)
*
|
2019-05-16 |
2020-11-19 |
Sanofi |
Expression of antigen-binding proteins in the nervous system
|
|
BR112021023024A2
(pt)
*
|
2019-05-16 |
2022-01-25 |
Qilu Pharmaceutical Co Ltd |
Anticorpo contra claudina 18a2 e uso do mesmo
|
|
TWI844684B
(zh)
*
|
2019-06-04 |
2024-06-11 |
大陸商普米斯生物技術（珠海）有限公司 |
一種抗ceacam5的單殖株抗體及其製備方法和用途
|
|
JP7617040B2
(ja)
*
|
2019-06-13 |
2025-01-17 |
プレステージ バイオファーマ リミテッド |
Ｃｔｈｒｃ１に特異的な新規抗体及びその使用
|
|
FR3099160B1
(fr)
*
|
2019-07-23 |
2022-05-06 |
Univ Grenoble Alpes |
Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
|
|
ES3059248T3
(en)
*
|
2019-07-26 |
2026-03-19 |
Sinocelltech Ltd |
Humanized anti-il17a antibody and use thereof
|
|
PH12022550239A1
(en)
*
|
2019-07-31 |
2022-12-19 |
Alector Llc |
Anti-ms4a4a antibodies and methods of use thereof
|
|
CA3147835A1
(en)
*
|
2019-08-16 |
2021-02-25 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Chimeric antigen receptors for treating myeloid malignancies
|
|
BR112022005666A2
(pt)
*
|
2019-09-26 |
2022-06-21 |
Univ Minnesota |
Compostos engatadores de nk que se ligam a antígenos virais e métodos de uso
|
|
WO2021058718A1
(en)
*
|
2019-09-26 |
2021-04-01 |
Roche Diagnostics Gmbh |
Anti-csf-1r antibody
|
|
US20220348664A1
(en)
*
|
2019-09-26 |
2022-11-03 |
WuXi Biologics Ireland Limited |
A novel anti-pd-l1/anti-lag-3 bispecific antibody and uses thereof
|
|
WO2021064009A1
(en)
*
|
2019-09-30 |
2021-04-08 |
Scirhom Gmbh |
Protein binders to irhom2 epitopes
|
|
US20240050529A1
(en)
|
2019-10-07 |
2024-02-15 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
|
KR20220092927A
(ko)
*
|
2019-11-04 |
2022-07-04 |
메디뮨 리미티드 |
신장 장애를 치료하기 위한 항 il-33 치료제
|
|
JP6761889B1
(ja)
*
|
2019-11-11 |
2020-09-30 |
株式会社Ｇｓｐエンタープライズ |
抗ヒトＣｒｉｐｔｏ−１抗体
|
|
US20220275103A1
(en)
*
|
2019-11-18 |
2022-09-01 |
CentricsBio, Inc. |
Anti-cd300c monoclonal antibody and biomarker thereof for preventing or treating cancer
|
|
EP4061849A4
(en)
*
|
2019-11-21 |
2024-05-29 |
Brown University |
BISPECIFIC ANTIBODIES AGAINST CHI3L1 AND CTLA4 WITH IMPROVED CYTOTOXIC EFFECTS ON TUMOR CELLS
|
|
AU2020395907A1
(en)
*
|
2019-12-06 |
2022-07-21 |
Universitair Ziekenhuis Antwerpen |
Combination immunotherapy of IL-15 and CD40 agonist in cancer treatment
|
|
IL293640A
(en)
*
|
2019-12-20 |
2022-08-01 |
Amgen Inc |
CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
|
|
CN119930824A
(zh)
*
|
2020-01-13 |
2025-05-06 |
真和制药有限公司 |
抗Gal3抗体和使用方法
|
|
KR20220131293A
(ko)
*
|
2020-01-24 |
2022-09-27 |
화이자 인코포레이티드 |
항-e-셀렉틴 항체, 조성물 및 사용 방법
|
|
US20230067811A1
(en)
|
2020-01-24 |
2023-03-02 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
|
US12692311B2
(en)
*
|
2020-01-29 |
2026-07-28 |
William Robert Arathoon Living Trust Dated August 29, 2016 |
Anti-MDR1 antibodies and uses thereof
|
|
US20230080224A1
(en)
*
|
2020-02-07 |
2023-03-16 |
Agency For Science, Technology And Research |
Antigen-binding molecules against alppl2 and/or alpp and uses thereof
|
|
AU2021219671A1
(en)
*
|
2020-02-10 |
2022-07-14 |
Regeneron Pharmaceuticals, Inc. |
Anti-Tmprss2 Antibodies and Antigen-Binding Fragments
|
|
EP4103618A4
(en)
*
|
2020-02-12 |
2024-05-01 |
The Scripps Research Institute |
LONG-ACTING GM-CSF AND METHODS OF USE
|
|
KR102626782B1
(ko)
*
|
2020-02-14 |
2024-01-19 |
주식회사 셀젠텍 |
B세포 성숙화 항원을 표적으로 하는 키메라 항원 수용체 및 이의 용도
|
|
CN115190886B
(zh)
*
|
2020-02-20 |
2026-04-28 |
马斯特里赫特大学 |
循环bmp10（骨形态发生蛋白10）的检测方法
|
|
GB202003632D0
(en)
*
|
2020-03-12 |
2020-04-29 |
Harbour Antibodies Bv |
SARS-Cov-2 (SARS2, COVID-19) antibodies
|
|
EP4130033A4
(en)
*
|
2020-03-30 |
2024-08-07 |
National Institutes of Biomedical Innovation, Health and Nutrition |
EPITOPE REGION BYPASSING BIPARATOPIC ANTIBODY AND PRODUCTION METHOD THEREOF
|
|
CR20220552A
(es)
|
2020-04-02 |
2023-01-17 |
Regeneron Pharma |
Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
|
|
KR102485892B1
(ko)
*
|
2020-04-09 |
2023-01-09 |
주식회사 에이프릴바이오 |
고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
|
|
BR112022020256A2
(pt)
|
2020-04-09 |
2023-01-03 |
Aprilbio Co Ltd |
anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, ácido nucleico, vetor de expressão, célula, composição, uso da composição e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo
|
|
JP7894321B2
(ja)
*
|
2020-04-28 |
2026-07-23 |
ソラ・バイオサイエンシズ・エルエルシー |
Ｔｄｐ－４３プロテイノパチーの処置のための組成物および方法
|
|
EP4149632A1
(en)
|
2020-05-14 |
2023-03-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind msln and cd3
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
WO2021242728A1
(en)
*
|
2020-05-26 |
2021-12-02 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cervical cancer by administering the pd-1 inhibitor antibody cemiplimab
|
|
MX2022014598A
(es)
|
2020-05-26 |
2023-03-31 |
Regeneron Pharma |
Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno.
|
|
MX2022014786A
(es)
|
2020-05-26 |
2023-01-16 |
Truebinding Inc |
Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
|
|
PE20230460A1
(es)
|
2020-05-29 |
2023-03-10 |
23Andme Inc |
Anticuerpos anti-cd200r1 y metodos de uso de estos
|
|
EP4161968A4
(en)
*
|
2020-06-04 |
2024-06-26 |
Selvax Pty Ltd. |
AGONISTIC ANTI-CD40 ANTIBODIES
|
|
WO2021252519A1
(en)
*
|
2020-06-08 |
2021-12-16 |
University Of Florida Research Foundation, Inc. |
Materials and methods for the diagnosis and treatment of cancer
|
|
CA3182384A1
(en)
*
|
2020-06-18 |
2021-12-23 |
Jay M. Short |
Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
CA3186065A1
(en)
*
|
2020-07-16 |
2022-01-20 |
Xiaohu FAN |
Cd19 binding molecules and uses thereof
|
|
CN116390941A
(zh)
*
|
2020-07-16 |
2023-07-04 |
南京传奇生物科技有限公司 |
多特异性嵌合抗原受体及其用途
|
|
MX2023000763A
(es)
|
2020-07-17 |
2023-02-13 |
Boehringer Ingelheim Int |
Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas.
|
|
TW202212354A
(zh)
*
|
2020-08-03 |
2022-04-01 |
美商健生生物科技公司 |
用於病毒治療劑中之多向生物運輸的材料及方法
|
|
TWI915400B
(zh)
*
|
2020-08-14 |
2026-02-21 |
日商中外製藥股份有限公司 |
單臂抗原結合分子及其用途
|
|
IL300704A
(en)
*
|
2020-08-18 |
2023-04-01 |
Omeros Corp |
Monoclonal antibodies, preparations and methods for detecting complement factor D
|
|
WO2022040596A1
(en)
*
|
2020-08-20 |
2022-02-24 |
Ambrx, Inc. |
Antibody-tlr agonist conjugates, methods and uses thereof
|
|
EP4209509A4
(en)
*
|
2020-09-03 |
2025-03-19 |
Harbour Biomed (Shanghai) Co., Ltd |
ROR1-TARGETTING ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, METHOD OF PREPARATION THEREOF AND USE THEREOF
|
|
WO2022056197A1
(en)
*
|
2020-09-11 |
2022-03-17 |
Janssen Biotech, Inc. |
Immune targeting molecules and uses thereof
|
|
CA3192465A1
(en)
*
|
2020-09-18 |
2022-03-24 |
Laure Bouchez |
Cd47-cd38 bispecific antibodies
|
|
JP7905328B2
(ja)
|
2020-09-18 |
2026-08-14 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｃｄ３８及び／又はｃｄ２８を結合する抗原結合分子及びその使用
|
|
CN115210262B
(zh)
*
|
2020-09-29 |
2023-07-14 |
昆明赛诺制药股份有限公司 |
人源化抗-cd22重组免疫毒素及其应用
|
|
EP4221752A4
(en)
*
|
2020-09-30 |
2024-12-04 |
Dren Bio, Inc. |
ANTI-CD94 ANTIBODIES AND METHODS OF USE THEREOF
|
|
US20240018231A1
(en)
*
|
2020-10-30 |
2024-01-18 |
Rush University Medical Center |
Intranasal immunotherapt for the treatment of alzheimer's disease
|
|
CN117126281A
(zh)
*
|
2020-11-09 |
2023-11-28 |
江苏中新医药有限公司 |
抗cd73单克隆抗体及其在制备肿瘤药物中的应用
|
|
CN114470189B
(zh)
*
|
2020-11-12 |
2024-01-16 |
达石药业(广东)有限公司 |
Ngf抗体在cipn性疼痛中的应用
|
|
WO2022129120A1
(en)
*
|
2020-12-17 |
2022-06-23 |
F. Hoffmann-La Roche Ag |
Anti-hla-g antibodies and use thereof
|
|
JP2024500115A
(ja)
*
|
2020-12-18 |
2024-01-04 |
エイシー イミューン ソシエテ アノニム |
抗体デリバリー
|
|
US12325752B2
(en)
*
|
2020-12-18 |
2025-06-10 |
Regeneron Pharmaceuticals, Inc. |
Immunoglobulin proteins that bind to NPR1 agonists
|
|
US20240034778A1
(en)
*
|
2020-12-22 |
2024-02-01 |
The Regents Of The University Of Michigan |
Amyloid-specific antibodies and uses thereof
|
|
US20250277031A1
(en)
*
|
2021-01-08 |
2025-09-04 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Antibody specifically binding to cd47 and antigen-binding fragment thereof
|
|
TW202241964A
(zh)
*
|
2021-01-08 |
2022-11-01 |
美商必治妥美雅史谷比公司 |
因子xia抑制劑之抗體及抗原結合肽及其用途
|
|
BR112023014103A2
(pt)
*
|
2021-03-04 |
2023-10-10 |
Boehringer Ingelheim Int |
Métodos para o tratamento de gpp
|
|
EP4305067A1
(en)
|
2021-03-09 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
US11859012B2
(en)
*
|
2021-03-10 |
2024-01-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and GPC3
|
|
EP4305207A2
(en)
|
2021-03-12 |
2024-01-17 |
Boehringer Ingelheim International GmbH |
Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
|
|
EP4308607A2
(en)
*
|
2021-03-18 |
2024-01-24 |
MedImmune Limited |
Therapeutic binding molecule that binds to ccr9
|
|
CA3214594A1
(en)
*
|
2021-03-24 |
2022-09-29 |
Janssen Biotech, Inc. |
Trispecific antibody targeting cd79b, cd20, and cd3
|
|
PE20241732A1
(es)
*
|
2021-03-31 |
2024-08-19 |
Merus Nv |
Dominios de union a pd-1 novedosos
|
|
EP4313311A1
(en)
*
|
2021-03-31 |
2024-02-07 |
Merus N.V. |
Multispecific binding moieties comprising novel pd-1 binding domains
|
|
PE20260568A1
(es)
*
|
2021-04-06 |
2026-03-10 |
Teneobio Inc |
Anticuerpos anti-cd19 y estructuras car-t
|
|
CN115260312B
(zh)
*
|
2021-04-30 |
2025-02-14 |
保诺科技（北京）有限公司 |
结合ox40的抗体或抗原结合片段
|
|
WO2022271884A2
(en)
*
|
2021-06-22 |
2022-12-29 |
Twist Bioscience Corporation |
Methods and compositions relating to covid antibody epitopes
|
|
CN117616123B
(zh)
*
|
2021-06-25 |
2024-11-08 |
中外制药株式会社 |
抗ctla-4抗体
|
|
US12448451B2
(en)
*
|
2021-06-25 |
2025-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CTLA-4 antibody and use thereof
|
|
IL308633B2
(en)
*
|
2021-06-25 |
2025-12-01 |
Chugai Pharmaceutical Co Ltd |
Use of anti-ctla-4 antibody
|
|
EP4370210A1
(en)
*
|
2021-07-14 |
2024-05-22 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
|
|
US20240352128A1
(en)
*
|
2021-08-25 |
2024-10-24 |
Nanjing GenScript Biotech Co., Ltd. |
ANTIBODIES AND VARIANTS THEREOF AGAINST HUMAN CD16a
|
|
CA3231484A1
(en)
|
2021-10-01 |
2023-04-06 |
Qinwen Mao |
Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
|
|
US11542340B1
(en)
*
|
2021-10-29 |
2023-01-03 |
Biodesix, Inc. |
Antibodies targeting pulmonary nodule specific biomarkers and uses thereof
|
|
WO2023107957A1
(en)
|
2021-12-06 |
2023-06-15 |
Regeneron Pharmaceuticals, Inc. |
Antagonist anti-npr1 antibodies and methods of use thereof
|
|
CN120282987A
(zh)
|
2022-11-30 |
2025-07-08 |
因特格尔莫来库乐有限公司 |
包括双特异性型式的针对紧密连接蛋白6的抗体
|
|
CN120513256B
(zh)
*
|
2023-01-20 |
2026-07-10 |
迈威(美国)生物治疗有限公司 |
抗淀粉样蛋白β原纤丝/低聚物抗体和其用途
|
|
US20240285789A1
(en)
*
|
2023-02-23 |
2024-08-29 |
University Of Utah Research Foundation |
Compositions and Methods for Killing PD-1 Positive Cells
|
|
WO2024194686A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
WO2025257181A1
(en)
*
|
2024-06-11 |
2025-12-18 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
|
|
WO2026132413A1
(en)
|
2024-12-20 |
2026-06-25 |
Bioarctic Ab |
Antibody against tdp-43
|